| Literature DB >> 26661166 |
Kavi Devraj1, Slobodan Poznanovic2, Christoph Spahn3, Gerhard Schwall2, Patrick N Harter4, Michel Mittelbronn4, Katia Antoniello5, Paolo Paganetti5, Andreas Muhs5, Mike Heilemann3, Richard A Hawkins6, André Schrattenholz7, Stefan Liebner4.
Abstract
Endothelial cells of the blood-brain barrier form a structural and functional barrier maintaining brain homeostasis via paracellular tight junctions and specific transporters such as P-glycoprotein. The blood-brain barrier is responsible for negligible bioavailability of many neuroprotective drugs. In Alzheimer's disease, current treatment approaches include inhibitors of BACE-1 (β-site of amyloid precursor protein cleaving enzyme), a proteinase generating neurotoxic β-amyloid. It is known that BACE-1 is highly expressed in endosomes and membranes of neurons and glia. We now provide evidence that BACE-1 is expressed in blood-brain barrier endothelial cells of human, mouse, and bovine origin. We further show its predominant membrane localization by 3D-dSTORM super-resolution microscopy, and by biochemical fractionation that further shows an abluminal distribution of BACE-1 in brain microvessels. We confirm its functionality in processing APP in primary mouse brain endothelial cells. In an Alzheimer's disease mouse model we show that BACE-1 is upregulated at the blood-brain barrier compared to healthy controls. We therefore suggest a critical role for BACE-1 at the blood-brain barrier in β-amyloid generation and in vascular aspects of Alzheimer's disease, particularly in the development of cerebral amyloid angiopathy.Entities:
Keywords: Alzheimer’s disease; BACE-1; blood–brain barrier; endothelium; β-amyloid
Mesh:
Substances:
Year: 2015 PMID: 26661166 PMCID: PMC4929696 DOI: 10.1177/0271678X15606463
Source DB: PubMed Journal: J Cereb Blood Flow Metab ISSN: 0271-678X Impact factor: 6.200